Abstract:Key Points Apoptosis, the cell-death programme that is mediated by proteases called caspases, is essential for tissue homeostasis, and its perturbed regulation underlies many diseases, including cancer. Commitment to apoptosis in response to diverse physiological cues and cytotoxic agents is governed by proteins of the Bcl2 family. Bcl2 and several pro-survival relatives associate with the mitochondrial outer membrane and the endoplasmic reticulum/nuclear membrane and maintain their integrity. Initiation of apoptosis requires not only pro-apoptotic family members such as Bax and Bak that closely resemble Bcl2, but also distant cousins that are related only by the small BH3 protein-interaction domain. The BH3-only proteins are sentinels that detect developmental death cues or intracellular damage. In healthy cells, they are restrained in diverse ways, including sequestration on the cytoskeleton. When unleashed by death signals, they switch off survival function by inserting their BH3 domain into a groove on their pro-survival relatives. Either Bax or Bak is required for apoptosis, but how they are activated or countermanded by Bcl2 remains uncertain. During apoptosis, Bax and Bak oligomerize in the mitochondrial outer membrane and probably breach its integrity, freeing pro-apoptotic proteins such as cytochrome c, which allows activation of caspase-9. The pro-survival Bcl2-like proteins can prevent cytochrome c release, and hence caspase-9 activation. They probably also regulate the activation of several other caspases, independently of mitochondrial damage. Impaired apoptosis is a central step towards neoplasia. Pro-survival Bcl2-like proteins can promote tumorigenesis, and certain pro-apoptotic relatives act as tumour suppressors. Moreover, the expression of family members is affected by other tumorigenic alterations (for example, p53 mutation). Conventional cytotoxic therapy indirectly induces apoptosis, but more effective outcomes should be achieved by direct activation of the apoptotic machinery. Promising approaches include impairing expression of pro-survival Bcl2-like proteins or identifying drugs that mimic the action of BH3-only proteins.

A Delicate Balance – the BCL-2 Family and Its Role in Apoptosis, Oncogenesis, and Cancer Therapeutics

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

Comprehensive review of Bcl‐2 family proteins in cancer apoptosis: Therapeutic strategies and promising updates of natural bioactive compounds and small molecules

B-cell Lymphoma-2 Family Proteins in the Crosshairs: Small Molecule Inhibitors and Activators for Cancer Therapy.

BCL-2 inhibition in haematological malignancies: Clinical application and complications

The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update

The Bcl-2 apoptotic switch in cancer development and therapy

Bcl-2 Family Proteins As Targets for Anticancer Drug Design

[Physiological Function and Structural Basis of Bcl-2 Family Proteins].

Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer

Recent advances in canonical versus non-canonical Ca2+-signaling-related anti-apoptotic Bcl-2 functions and prospects for cancer treatment

Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review

The Bcl2 family: regulators of the cellular life-or-death switch

Therapeutics targeting BCL2 family proteins

The Bcl-2 Family: Ancient Origins, Conserved Structures, and Divergent Mechanisms

[Progress in Small-Molecule Inhibitors of Bcl-2 Family Proteins].

The BCL-2 protein family: opposing activities that mediate cell death

Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family

Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents

Bcl-2 proteins and calcium signaling: complexity beneath the surface